

Publisher: Bentham Science Publishers
E-ISSN: 2212-3873|15|2|135-144
ISSN: 1871-5303
Source: Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.15, Iss.2, 2015-06, pp. : 135-144
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content




VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets, Vol. 11, Iss. 5, 2011-01 ,pp. :



